Release date: 2013-07-17
Recently, TYRX Corporation of the United States announced that a new generation of absorbable AIGHRR R absorbable antibacterial capsules has been approved by the FDA. The AIGISRx series of antibacterial capsules are used to encapsulate devices such as cardiac pacemakers and implantable cardiac defibrillators to prevent infections caused by heart implant devices (CIED). R represents the absorbable model in AIGHRRx.
As the number of patients implanted with CIED increases, the number of people with CIED infection increases accordingly. Encapsulate with AGIGRax before implanting a pacemaker or defibrillator. After 7-10 days, AIGHRR releases antibiotics in the body to reduce the risk of postoperative infection. According to the intranet review of TYRX's research report, the incidence of severe infection was 0.1% after the use of AGIGRax, while the control group was 1.9%. AIGISRx said in a press release that AIGHRRx can reduce the risk of infection by 70% to 100%.
The new generation of AIGHRR R adds an absorbable advantage that will be degraded and absorbed in the human body after 3 months. AIGISRx R was approved by the Health Canada in January and is expected to be launched in the US market in the second half of this year.
Source: Kexun
Towing Rope,Car Yellow Tow Rope,Roadside Emergency Tow Strap,Emergency Tow Strap For Car
Ningbo Zhihao Car Accessories Co.,Ltd. , https://www.zhihaoautoparts.com